Xiang Yu Vincent Gao

Mr. Xiang Yu Vincent Gao

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Gels
Verified
Journal Article
Open access
PDF file
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
BCBenjamin R Caruso
Benjamin R Caruso
Weimin LiWeimin Li
Weimin Li
Breast cancer is the most common malignancy among women and is the second leading cause of cancer-related death for women. Depending on the tumor grade and stage, breast cancer is primarily treated with surgery and antineoplastic therapy. Direct or indirect side effects, emotional trauma, and unpredictable outcomes accompany these traditional therapies, calling for therapies that could improve the overall treatment and recovery experiences of patients. Hydrogels, biomimetic materials with 3D network structures, have shown great promise for augmenting breast cancer therapy. Hydrogel implants can be made with adipogenic and angiogenic properties for tissue integration. 3D organoids of malignant breast tumors grown in hydrogels retain the physical and genetic characteristics of the native tumors, allowing for post-surgery recapitulation of the diseased tissues for precision medicine assessment of the responsiveness of patient-specific cancers to antineoplastic treatment. Hydrogels can also be used as carrier matrices for delivering chemotherapeutics and immunotherapeutics or as post-surgery prosthetic scaffolds. The hydrogel delivery systems could achieve localized and controlled medication release targeting the tumor site, enhancing efficacy and minimizing the adverse effects of therapeutic agents delivered by traditional procedures. This review aims to summarize the most recent advancements in hydrogel utilization for breast cancer post-surgery tissue reconstruction, tumor modeling, and therapy and discuss their limitations in clinical translation.

7 July 2025 in JMIR Preprints
Verified
Preprint
Open access
HTHardeep S. Tiwana
Hardeep S. Tiwana
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
KFKevin Fujita
Kevin Fujita
BLBenjamin A. Lerner
Benjamin A. Lerner
MLMichael Z. Lerner
Michael Z. Lerner
BACKGROUND Retrograde cricopharyngeus dysfunction (R-CPD) is a recently described condition characterized by the lifelong abelchia. R-CPD remains unfamiliar to most clinicians. Comparatively, information regarding R-CPD has proliferated rapidly on the internet. OBJECTIVE This study aimed to assess public awareness, interest, and patterns of information-seeking behavior related to R-CPD symptoms, diagnosis, and treatment by analyzing the relative search volumes (RSV) of 24 terms related to R-CPD in the United States using the Google Trends database. METHODS Using Google Trends, data from Google Search queries from the United States related to R-CPD between January 2013 to May 2024 were obtained. The means of RSV from 2013 to 2018 were compared to RSV from 2019 (when R-CPD was officially defined) to the present. Comparisons of the RSV means between these two periods were performed using paired t-tests with p-value <0.05 considered statistically significant. RESULTS The mean RSV of “R-CPD” increased by 116% between 2013-2018 and 2019-2024 (11.5±3.9 to 24.6±15.4, p<0.002). Similar significant trends were observed for other terms, including “why can’t I burp” (4.3±4.8 to 17.6±4.8, p<0.002), “can’t burp” (5.9±1.2 to 9.3±1.6, p<0.002), “need to burp” (35.7±10.0 to 61.7±9.9, p<0.002), and “no burp” (10.9±4.0 to 18.4±5.9, p<0.002). Across all terms, top metropolitan areas showed consistently higher search volumes compared to top regions. CONCLUSIONS The significant increase in queries related to R-CPD likely reflects an increased awareness and interest in R-CPD throughout the United States. Relatively higher search volumes in metropolitan areas may reflect increased awareness, or even prevalence, of this condition in that setting. CLINICALTRIAL

1 January 2026 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
JBJessica Y. Bae
Jessica Y. Bae
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
JDJosephine K. Dermawan
Josephine K. Dermawan
JHJessica A. Hellyer
Jessica A. Hellyer
Background: Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management. Case Presentation: We report a case of primary pulmonary NUT carcinoma diagnosed in a 59‐year‐old male with a never‐smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed CDKN2A mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis. Conclusion: Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first‐line treatments include platinum‐based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.

30 September 2026 in Clinical Endoscopy
Verified
Journal Article
Open access
DKDivyanshoo R. Kohli
Divyanshoo R. Kohli
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
WSWichit Srikureja
Wichit Srikureja
JBJack Brandabur
Jack Brandabur
SCShih-Ting Chiu
Shih-Ting Chiu
NPNishant Puri
Nishant Puri
Background/Aims: Pancreatic duct (PD) stent selection impacts migration and retention. We evaluated risk factors for migration versus inappropriate retention of PD stents at a high volume center using a standardized stent management protocol.Methods: Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) with PD stenting were retrospectively categorized by stent status at 2 weeks post-ERCP. Spontaneous migration was defined as absence of a PD stent on follow-up imaging, while inappropriate retention was defined as persistence of a non-flanged PD stent within the duct. The primary endpoint was PD stent retention at 2 weeks. Secondary endpoints included predictors of inappropriate retention and the need for endoscopic stent removal.Results: A total of 482 patients underwent ERCP for biliary (n=289), pancreatic (n=181), or dual (n=12) indications. Non-flanged PD stents for biliary vs. pancreatic indications were 74.4% vs. 31.5% (p3cm (OR, 2.5; 95% CI, 1.23–5.07). Inappropriate retention of non-flanged stents occurred in 29 patients (12.5%), with only 5 (2.2%) requiring endoscopic removal due to mechanical obstruction.Conclusions: Inappropriate retention of short, narrow caliber, non flanged PD stents is infrequent and rarely requires endoscopic removal.

1 June 2025 in Annals of Thyroid
Verified
Journal Article
Open access
PDF file
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
AYAllison Young
Allison Young
JHJessica Hellyer
Jessica Hellyer
Background: Thyroblastoma, formerly called malignant thyroid teratoma, is an exceedingly rare germ cell malignancy with a poor prognosis. Specific treatment guidelines are nonexistent due to the rarity of this disease. This case report highlights the outcomes and management of a malignant primary thyroid teratoma in a pregnant adult. There is limited information on the nonsurgical management of this disease with no systematic reviews on the outcomes of chemoradiation compared to chemotherapy alone or comparisons between different chemotherapy regimens. The primary objective of our systematic review is to compare the median overall survival (mOS) of patients treated with chemoradiation compared to chemotherapy alone. Secondary objective is to compare mOS of patients treated with cisplatin-based regimens to non-cisplatin regimens. Case Description: A case of thyroblastoma in a 30-year-old patient at 11 weeks gestation is reported. The tumor was located in the thyroid with lymph node metastasis. Following R1 resection, adjuvant chemotherapy with bleomycin, etoposide, and cisplatin was administered until uncomplicated delivery at 36 weeks followed by chemoradiation with cisplatin. The patient is alive without evidence of disease 24 months from diagnosis. A systematic search of PubMed and Google Scholar for case series and reports of adults with thyroblastoma who underwent chemotherapy with reported follow-up times up to July 2024 was conducted. A total of 213 articles were found and assessed for eligibility by one reviewer. Of those, 18 articles reporting on 22 cases were included in our analysis. Twenty-two cases of patients with thyroblastomas were analyzed with a median age of 40 years and mOS of 44 months. Patients treated with chemoradiation had higher mOS than chemotherapy alone (53 vs. 24 months). Cases with cisplatin-based regimens had a higher mOS than non-cisplatin regimens (22 vs. 13 months). Conclusions: Our case is an example of trimodality therapy leading to long-term survival in a patient with thyroblastoma. It also supports the use of platinum-based regimens. Additionally, bleomycin, etoposide, and cisplatin is well tolerated during pregnancy. Our systematic review supports the use of concurrent chemoradiation for curative treatment of locally advanced thyroblastoma and platinum-based regimens in thyroblastomas.

1 October 2026 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
XGXiang Yu Vincent Gao
Xiang Yu Vincent Gao
NGNency Ganatra
Nency Ganatra
AAAhmed Abdelhakeem
Ahmed Abdelhakeem
NTNugyen Tran
Nugyen Tran
MRMichael Rutenberg
Michael Rutenberg
HBHani Babiker
Hani Babiker
Background: Pancreatic adenosquamous carcinoma (PASC) is a rare 1–4% of all pancreatic cancers and an aggressive pancreatic malignancy characterized by mixed adenocarcinoma and squamous histologies. Even after surgical intervention, patients with PASC have a lower median overall survival (mOS) than those with the more prevalent pancreatic ductal adenocarcinoma (PDAC). Secondary to its rarity, there are no formal guidelines, published clinical trials, or systematic reviews on treatment strategies for managing PASC. The primary objective was to assess mOS in months among patients with local non-metastatic disease treated with different modalities. Secondary objectives were to assess differences in mOS between chemotherapy regimens and according to surgical resectability and initial tumor size, as well as to evaluate the independent association between chemotherapy and overall survival using multivariable Cox proportional hazards regression. Methods: A comprehensive search of PubMed/MEDLINE, Google Scholar, and Cochrane Library for all full-text articles up to July 2026 identified 503 studies that were conducted globally. 72 case series and reports that met inclusion criteria were selected following PRISMA guidelines. Results: A total of 89 patients from 72 publications were included. The median age was 66 (interquartile range, 60–72) years, 49 patients were male, and the median tumor diameter was 48 (interquartile range, 35–74) mm. Forty-nine patients received chemotherapy and 55 underwent surgical resection. Eighty-eight patients had both survival time and vital status and were included in survival analyses, with 56 deaths observed. In the primary treatment-modality analysis, among surgically unresectable patients, mOS was 3.0 months with neither chemotherapy nor radiotherapy, 6.0 months with chemotherapy alone, 13.7 months with radiotherapy alone, and 15.5 months with combined chemotherapy and radiotherapy (P=0.01). Among surgically resectable patients, mOS was 10.8 months with neither chemotherapy nor radiotherapy, 6.7 months with chemotherapy alone, 4.0 months with radiotherapy alone, and 26.0 months with combined chemotherapy and radiotherapy (P=0.03). In the secondary multivariable Cox model, chemotherapy was independently associated with improved overall survival [hazard ratio (HR), 0.41; 95% confidence interval (CI): 0.24–0.70; P=0.001], while surgical resection was not independently associated with survival (HR, 1.17; 95% CI: 0.58–2.34; P=0.66). mOS across all patients was 8.0 months (95% CI: 6.5–12.0). Median survival differed significantly according to disease extent, ranging from 33.0 months among patients with borderline resectable disease to 4.0 months among patients with metastatic disease (P=0.0004). Restricted mean survival at 24 months was 15.6 months with chemotherapy versus 8.2 months without chemotherapy. The association between chemotherapy and improved survival remained significant across most sensitivity analyses. Among patients with unresectable disease, mOS was 18.0 months with S-1, 5.4 months with gemcitabine, and 4.0 months with 5-fluorouracil (P=0.09). Conclusions: Combined chemotherapy and radiotherapy were associated with the longest mOS among both surgically resectable and unresectable patients in the primary treatment-modality analysis.